Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å lære om studiemedisinen PF-08634404 i kombinasjon med kjemoterapi ved gastroøsofageal kreft

9. oktober 2026 oppdatert av: Pfizer

EN FAZE 2/3 INTERVENSJONSTUDIE AV PF-08634404 I KOMBINASJON MED KEMOTERAPI BEHANDLINGSNAIVE DELTAKERE MED LOKALT AVANSERT ELLER METASTATISK MAKRE, GASTROESOFAGEALT KNUTEPUNKT ELLER SPISERØRSADENOKARSINOM

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.

The study has two parts:

  • In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
  • In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.

The treatment will be given in repeated time periods called cycles.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

840

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Har ikke rekruttert ennå
        • London Health Sciences Centre - Verspeeten Family Cancer Centre
    • California
      • Atascadero, California, Forente stater, 93422
        • Rekruttering
        • UCLA Hematology/Oncology - Atascadero
      • Burbank, California, Forente stater, 91505
        • Rekruttering
        • UCLA Hematology/Oncology - Burbank
      • Encino, California, Forente stater, 91436
        • Rekruttering
        • UCLA Hematology/Oncology - Encino
      • Marina del Rey, California, Forente stater, 90292
        • Rekruttering
        • UCLA Hematology/Oncology - Marina del Rey
      • Porter Ranch, California, Forente stater, 91326
        • Rekruttering
        • UCLA Hematology/Oncology - Porter Ranch
      • San Francisco, California, Forente stater, 94158
        • Har ikke rekruttert ennå
        • UCSF Helen Diller Family Comprehensive Cancer Center
      • San Francisco, California, Forente stater, 94158
        • Har ikke rekruttert ennå
        • UCSF Investigational Drugs Pharmacy
      • San Luis Obispo, California, Forente stater, 93401
        • Rekruttering
        • UCLA Hematology/Oncology - San Luis Obispo
      • Santa Barbara, California, Forente stater, 93101
        • Rekruttering
        • UCLA Hematology/Oncology - Santa Barbara
      • Santa Monica, California, Forente stater, 90404
        • Rekruttering
        • UCLA Hematology/Oncology - Santa Monica
    • Colorado
      • Aurora, Colorado, Forente stater, 80012
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Boulder, Colorado, Forente stater, 80303
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Centennial, Colorado, Forente stater, 80112
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Colorado Springs, Colorado, Forente stater, 80907
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Colorado Springs, Colorado, Forente stater, 80923
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Denver, Colorado, Forente stater, 80218
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Denver, Colorado, Forente stater, 80220
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Englewood, Colorado, Forente stater, 80113
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Lakewood, Colorado, Forente stater, 80228
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Littleton, Colorado, Forente stater, 80120
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Lone Tree, Colorado, Forente stater, 80124
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Longmont, Colorado, Forente stater, 80504
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Pueblo, Colorado, Forente stater, 81003
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Thornton, Colorado, Forente stater, 80260
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
    • Florida
      • Daytona Beach, Florida, Forente stater, 32117
        • Har ikke rekruttert ennå
        • Florida Cancer Specialists
      • Fleming Island, Florida, Forente stater, 32003
        • Har ikke rekruttert ennå
        • Florida Cancer Specialists
      • Palm Beach Gardens, Florida, Forente stater, 33410
        • Har ikke rekruttert ennå
        • Florida Cancer Specialists
      • Sebring, Florida, Forente stater, 33870
        • Har ikke rekruttert ennå
        • Florida Cancer Specialists
      • Wellington, Florida, Forente stater, 33414
        • Har ikke rekruttert ennå
        • Florida Cancer Specialists
      • West Palm Beach, Florida, Forente stater, 33401
        • Har ikke rekruttert ennå
        • Florida Cancer Specialists
    • Illinois
      • Arlington Heights, Illinois, Forente stater, 60005
        • Rekruttering
        • Illinois Cancer Specialists
      • Bloomington, Illinois, Forente stater, 61704
        • Rekruttering
        • Illinois CancerCare - Bloomington
      • Chicago, Illinois, Forente stater, 60631
        • Rekruttering
        • Illinois Cancer Specialists
      • Galesburg, Illinois, Forente stater, 61401
        • Rekruttering
        • Illinois CancerCare - Galesburg
      • Niles, Illinois, Forente stater, 60714
        • Rekruttering
        • Illinois Cancer Specialists
      • Ottawa, Illinois, Forente stater, 61350
        • Rekruttering
        • Illinois CancerCare-Ottawa-Fox River Cancer Center
      • Pekin, Illinois, Forente stater, 61554
        • Rekruttering
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Forente stater, 61615
        • Rekruttering
        • Illinois CancerCare, P.C.
      • Peru, Illinois, Forente stater, 61354
        • Rekruttering
        • Illinois CancerCare-Peru - Valley Regional Cancer Center
      • Washington, Illinois, Forente stater, 61571
        • Rekruttering
        • Illinois CancerCare-Washington
    • Maryland
      • Annapolis, Maryland, Forente stater, 21401
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Bethesda, Maryland, Forente stater, 20817
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Brandywine, Maryland, Forente stater, 20613
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Columbia, Maryland, Forente stater, 21044
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Germantown, Maryland, Forente stater, 20876
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Largo, Maryland, Forente stater, 20774
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Rockville, Maryland, Forente stater, 20850
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Silver Spring, Maryland, Forente stater, 20904
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
    • Nevada
      • Reno, Nevada, Forente stater, 89502
        • Rekruttering
        • Renown Regional Medical Center
      • Reno, Nevada, Forente stater, 89502
        • Rekruttering
        • Renown Health Medical Oncology
      • Reno, Nevada, Forente stater, 89502
        • Rekruttering
        • Renown Office of Clinical Research
    • New Jersey
      • Morristown, New Jersey, Forente stater, 07960
        • Har ikke rekruttert ennå
        • Atlantic Health System
      • Summit, New Jersey, Forente stater, 07901
        • Har ikke rekruttert ennå
        • Atlantic Health System / Overlook Medical Center
    • New York
      • Long Island City, New York, Forente stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
      • Long Island City, New York, Forente stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - Main Campus
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
      • New York, New York, Forente stater, 10022
        • Rekruttering
        • Rockefeller Outpatient Pavilion (53rd Street)
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45245
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
      • Cincinnati, Ohio, Forente stater, 45242
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
      • Cincinnati, Ohio, Forente stater, 45211
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
      • Fairfield, Ohio, Forente stater, 45014
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
    • Pennsylvania
      • Bensalem, Pennsylvania, Forente stater, 19020
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Doylestown, Pennsylvania, Forente stater, 18901
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Horsham, Pennsylvania, Forente stater, 19044
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Langhorne, Pennsylvania, Forente stater, 19047
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Media, Pennsylvania, Forente stater, 19063
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Sellersville, Pennsylvania, Forente stater, 18960
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Wynnewood, Pennsylvania, Forente stater, 19096
        • Rekruttering
        • Alliance Cancer Specialists, PC
    • Texas
      • Irving, Texas, Forente stater, 75063
        • Rekruttering
        • US Oncology Investigational Products Center (IPC)
    • Virginia
      • Arlington, Virginia, Forente stater, 22201
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Chesapeake, Virginia, Forente stater, 23320
        • Rekruttering
        • Virginia Oncology Associates
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Hampton, Virginia, Forente stater, 23666
        • Rekruttering
        • Virginia Oncology Associates
      • Manassas, Virginia, Forente stater, 20110
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Newport News, Virginia, Forente stater, 23606
        • Rekruttering
        • Virginia Oncology Associates
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Virginia Oncology Associates
      • Reston, Virginia, Forente stater, 20190
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Virginia Beach, Virginia, Forente stater, 23456
        • Rekruttering
        • Virginia Oncology Associates
      • Woodbridge, Virginia, Forente stater, 22191
        • Rekruttering
        • Virginia Cancer Specialists, PC
    • Washington
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington Medical Center
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Forente stater, 98104
        • Rekruttering
        • Harborview Medical Center
      • Paris, Frankrike, 75015
        • Rekruttering
        • Hôpital Européen Georges Pompidou
    • Central District
      • Petah Tikva, Central District, Israel, 4941492
        • Rekruttering
        • Rabin Medical Center
    • HA Merkaz
      • Ramat Gan, HA Merkaz, Israel, 5265601
        • Rekruttering
        • Sheba Medical Center
    • TELL ABĪB
      • Tel Aviv, TELL ABĪB, Israel, 6423906
        • Rekruttering
        • Sourasky Medical Center
      • Milan, Italia, 20141
        • Rekruttering
        • Istituto Europeo di Oncologia IRCCS
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510655
        • Rekruttering
        • The Sixth Affiliated hospital, Sun Yat-sen University
    • Hubei
      • Wuhan, Hubei, Kina, 430079
        • Rekruttering
        • Hubei Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200031
        • Rekruttering
        • Zhongshan Hospital,Fudan University
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • Sichuan Cancer hospital
      • Bayamón, Puerto Rico, 00959
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Bayamón Office
    • United States
      • Manati, United States, Puerto Rico, 00674
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Manati Office
    • Barcelona [barcelona]
      • Barcelona, Barcelona [barcelona], Spania, 08035
        • Rekruttering
        • Hospital Universitari Vall d'Hebron
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spania, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre
    • Ourense [orense]
      • Ourense, Ourense [orense], Spania, 32005
        • Har ikke rekruttert ennå
        • Complexo Hospitalario Universitario de Ourense
      • Tainan, Taiwan, 704302
        • Rekruttering
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10002
        • Rekruttering
        • National Taiwan University Hospital
      • Taipei, Taiwan, 11217
        • Rekruttering
        • Taipei Veterans General Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
  • Evidence of locally advanced or metastatic disease.
  • Eastern Cooperative Oncology Group performance status (ECOG) 0-1
  • No prior systemic therapy for advanced or metastatic disease.
  • Adequate hepatic, liver, and renal function
  • HER-2 negative status based on local testing
  • PD-L1 positive status based on local testing

Exclusion Criteria:

  • Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
  • Clinically significant risk of hemorrhage or fistula
  • Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
  • Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
  • Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
  • Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 2 Portion

PF-08634404 + Chemotherapy

Participants will receive PF-08634404 intravenously.

Andre navn:
  • SSGJ-707

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Eksperimentell: Phase 3: Arm A

PF-08634404 + Chemotherapy

Participants will receive PF-08634404 intravenously.

Andre navn:
  • SSGJ-707

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Aktiv komparator: Phase 3: Arm B

Nivolumab + Chemotherapy

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Participants will receive Nivolumab intravenously.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator.

Approximately 4 years
Phase 2: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years

PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: Overall Survival (OS)
Tidsramme: Approximately 4 years

OS is defined as the time from the date of randomization to the date of death due to any cause.

Approximately 4 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fase 2: Forekomst av anti-legemiddel-antistoff (ADA) mot PF-08634404
Tidsramme: Omtrent 21 måneder
Omtrent 21 måneder
Fase 3: Forekomst av ADA mot PF-08634404
Tidsramme: Omtrent 21 måneder
Omtrent 21 måneder
Fase 3: Endring fra utgangspunkt i Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) totalscore
Tidsramme: Omtrent 4 år
Omtrent 4 år
Fase 3: Tid til definitiv forverring i FACT-Ga totalpoengsum
Tidsramme: Omtrent 4 år
Omtrent 4 år
Fase 3: Tid til definitiv forverring i Gastric Cancer Subscale (GaCS)-skår
Tidsramme: Omtrent 4 år
Omtrent 4 år
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 2: Overall Survival (OS)
Tidsramme: Approximately 4 years

OS is defined as the time from the date of first dose to the date of death due to any cause.

Approximately 4 years
Phase 2: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed.

Through 90 days after the last study intervention; Approximately 4 years
Phase 2: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months

Predose and postdose concentrations of PF-08634404

Approximately 21 months
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years

ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR.

Approximately 4 years
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator.

Approximately 4 years
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first

Approximately 4 years
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years

DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Tidsramme: Approximately 4 years

PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first

Approximately 4 years
Phase 3: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s)

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed.

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months

Predose and postdose concentrations of PF-08634404

Approximately 21 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. mai 2026

Primær fullføring (Antatt)

22. juli 2031

Studiet fullført (Antatt)

21. juli 2032

Datoer for studieregistrering

Først innsendt

30. januar 2026

Først innsendt som oppfylte QC-kriteriene

30. januar 2026

Først lagt ut (Faktiske)

6. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere